In conclusion, our study displayed that SZU-101 (a TLR7 agonist synthesized by our group) and JQ-1 (a well-defined BRD4 inhibitor) could be administrated in combination to achieve better repressive effects on tumor growth and metastasis in both murine breast cancer and melanoma models. Here, TLR7 is linked to breast cancer.